FDA Fully Lifts Clinical Hold on Intellia Therapeutics' CRISPR Gene Therapy Trials for ATTR Amyloidosis on March 04, 2026 ATTR-CM ATTRv-PN Clinical Clustered Regularly Interspaced Short Palindromic Repeats Degree or extent gene therapy Intellia nex-z nexiguran United States Food and Drug Administration ziclumeran +
FDA Lifts Clinical Hold on Intellia's MAGNITUDE-2 Phase 3 Trial for Nex-Z in ATTRv-PN on January 29, 2026 ATTRv-PN Clustered Regularly Interspaced Short Palindromic Repeats Gene Modification Intellia MAGNITUDE-2 nex-z Study on Hold United States Food and Drug Administration +